Jaden Schutt never tallied a double-digit scoring outing in his 14 appearances as a Duke basketball freshman in 2022-23. And ...

Unable to function offensively against No 16 Duke’s quick and aggressive defense, 18th-ranked Cal suffered its worst loss of its best season in 12 years on Thur ...

The Chronicle compiled a list of opportunities to celebrate King’s life and continue his tradition of service at Duke and in ...

The Hornets are sending Richards and a second-round pick to Phoenix for Josh Okogie and three second-round picks, league ...

Scientists at Duke University's Human Vaccine Institute have made a significant advance in the quest for an HIV vaccine.

Duke Graduate and Professional Student Government heard a presentation from University administrators addressing Duke's ...

Duke poured in 17 3-pointers, including six from freshman Kon Knueppel, as the Blue Devils rolled over last-place Miami in ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

Duke neuroscientist Kafui Dzirasa wants nothing less than to reengineer the brain’s electrical patterns to treat anxiety, ...